Function of LRRK2 in Parkinson's disease

Progress in Biochemistry and Biophysics

Volumn 37, Issue 10, 2010, Pages 1059-1066

  Zhu, Fei Zhou ^a   Xia, Kun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Functional research; Leucine rich repeat kinase (LRRK2); Parkinson's disease

Indexed keywords

EID: 79951888273     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2010.00197     Document Type: Article

References (68)

1. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 2004, 44(4): 601-607 (Pubitemid 39531225)
2. Tan L C S, Venketasubramanian N, Hong C Y, et al. Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology, 2004, 62: 1999-2004 (Pubitemid 38738211)
3. Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol, 2005, 18(4): 363-369 (Pubitemid 41104797)
4. Di Fonzo A, Chien H F, Socal M, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 2007, 68(19): 1557-1562 (Pubitemid 46717978)
5. Paisan-Ruiz C, Jain S, Evans E W, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 2004, 44(4): 595-600 (Pubitemid 39531224)
6. Lesage S, Durr A, Brice A. LRRK2: a link between familial and sporadic Parkinson's disease?. Pathol Biol(Paris), 2007, 55(2): 107-110
7. Mata I F, Wedemeyer W J, Farrer M J, et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci, 2006, 29(5): 286-293
8. Mata I F, Kachergus J M, Taylor J P, et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics, 2005, 6 (4): 171-177 (Pubitemid 41720888)
9. Funayama M, Hasegawa K, Kowa H, et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol, 2002, 51(3): 296-301 (Pubitemid 34206285)
10. Zimprich A, Muller-Myhsok B, Farrer M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet, 2004, 74(1): 11-19 (Pubitemid 38085234)
11. Berg D, Schweitzer K, Leitner P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain, 2005, 128(Pt 12): 3000-3011
12. Skipper L, Shen H, Chua E, et al. Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology, 2005, 65(8): 1319-1321 (Pubitemid 41508237)
13. Paisan-Ruiz C, Lang A E, Kawarai T, et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology, 2005, 65(5): 696-700 (Pubitemid 41285847)
14. Zabetian C P, Samii A, Mosley A D, et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology, 2005, 65(5): 741-744 (Pubitemid 41285855)
15. Mata I F, Taylor J P, Kachergus J, et al. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci Lett, 2005, 382 (3): 309-311 (Pubitemid 40733642)
16. Farrer M, Stone J, Mata I F, et al. LRRK2 mutations in Parkinson disease. Neurology, 2005, 65(5): 738-740 (Pubitemid 41285854)
17. Khan N L, Jain S, Lynch J M, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain, 2005, 128(Pt 12): 2786-2796 (Pubitemid 41746633)
18. Lu C S, Simons E J, Wu-Chou Y H, et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat Disord, 2005, 11(8): 521-522 (Pubitemid 41627846)
19. Funayama M, Hasegawa K, Ohta E, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol, 2005, 57(6): 918-921 (Pubitemid 40798631)
20. Di Fonzo A, Wu-Chou Y H, Lu C S, et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics, 2006, 7 (3): 133-138 (Pubitemid 44078290)
21. Fung H C, Chen C M, Hardy J, et al. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol, 2006, 6: 47
22. Giasson B I, Covy J P, Bonini N M, et al. Biochemical and pathological characterization of Lrrk2. Ann Neurol, 2006, 59 (2): 315-322 (Pubitemid 43202485)
23. Taymans J M, Van Den Haute C, Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem, 2006, 98(3): 951-961 (Pubitemid 44051294)
24. Simon-Sanchez J, Herranz-Perez V, Olucha-Bordonau F, et al. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur J Neurosci, 2006, 23(3): 659-666
25. Melrose H, Lincoln S, Tyndall G, et al. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience, 2006, 139(3): 791-794 (Pubitemid 44308089)
26. Galter D, Westerlund M, Carmine A, et al. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol, 2006, 59 (4): 714-719
27. Higashi S, Moore D J, Colebrooke R E, et al. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J Neurochem, 2007, 100(2): 368-381 (Pubitemid 46010998)
28. Biskup S, Moore D J, Celsi F, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol, 2006, 60(5): 557-569 (Pubitemid 44871798)
29. Hatano T, Kubo S, Imai S, et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet, 2007, 16(6): 678-690 (Pubitemid 46585667)
30. Greggio E, Jain S, Kingsbury A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis, 2006, 23(2): 329-341 (Pubitemid 44097032)
31. Smith W W, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA, 2005, 102 (51): 18676-18681 (Pubitemid 43011285)
32. West A B, Moore D J, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA, 2005, 102(46): 16842-16847 (Pubitemid 41688864)
33. Gloeckner C J, Kinkl N, Schumacher A, et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet, 2006, 15(2): 223-232 (Pubitemid 43125977)
34. Smith W W, Pei Z, Jiang H, et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci, 2006, 9(10): 1231-1233 (Pubitemid 44454261)
35. Lewis P A, Greggio E, Beilina A, et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun, 2007, 357(3): 668-671 (Pubitemid 46653831)
36. Li X, Tan Y C, Poulose S, et al. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem, 2007, 103(1): 238-247 (Pubitemid 47404210)
37. Xiong Y, Coombes C E, Kilaru A, et al. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet, 2010, 6(4): e1000902
38. Iaccarino C, Crosio C, Vitale C, et al. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet, 2007, 16(11): 1319-1326 (Pubitemid 47055127)
39. Liu Z, Wang X, Yu Y, et al. A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci USA, 2008, 105(7): 2693-2698 (Pubitemid 351520575)
40. Wang D, Tang B, Zhao G, et al. Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener, 2008, 3(1): No.3
41. Sheng D, Qu D, Kwok K H, et al. Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet, 2010, 6(4): e1000914
42. Li Y, Liu W, Oo T F, et al. Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nature Neuroscience, 2009, 12(7): 826-828
43. Tong Y, Yamaguchi H, Giaime E, et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of {alpha}-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA, 2010, 107(21): 9879-9884
44. Guo L, Gandhi P N, Wang W, et al. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res, 2007, 313(16): 3658-3670 (Pubitemid 47404550)
45. Ito G, Okai T, Fujino G, et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry, 2007, 46(5): 1380-1388 (Pubitemid 46208485)
46. West A B, Moore D J, Choi C, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet, 2007, 16(2): 223-232 (Pubitemid 46179004)
47. Ko H S, Bailey R, Smith W W, et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci USA, 2009, 106(8): 2897-2902
48. Ding X, Goldberg M S. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PloS One, 2009, 4(6): e5949
49. Gandhi P N, Wang X, Zhu X, et al. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res, 2008, 86(8): 1711-1720 (Pubitemid 351859422)
50. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in Parkinsonian neurodegeneration?. J Neurochemistry, 2009, 110(5): 1514-1522
51. Ho C C, Rideout H J, Ribe E, et al. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci, 2009, 29(4): 1011-1016
52. Kumar A, Greggio E, Beilina A, et al. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One, 2010, 5 (1): e8730
53. Imai Y, Gehrke S, Wang H Q, et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J, 2008, 27(18): 2432-2443
54. Gillardon F. Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro. Neuroscience, 2009, 163(2): 533-539
55. Shin N, Jeong H, Kwon J, et al. LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res, 2008, 314(10): 2055-2065
56. Qing H, Wong W, McGeer E G, et al. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun, 2009, 387(1): 149-152
57. Samann J, Hegermann J, Gromoff E V, et al. Caenorhabditis elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem, 2009, 284: 16482-16491
58. Hsu C H, Chan D, Greggio E, et al. MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem, 2010, 112(6):1593-1604
59. Gloeckner C J, Schumacher A, Boldt K, et al. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem, 2009, 109(4): 959-968
60. Liou A K, Leak R K, Li L, et al. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol Dis, 2008, 32(1): 116-124
61. Carballo-Carbajal I, Weber-Endress S, Rovelli G, et al. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal, 2010, 22(5):821-827
62. Macleod D, Dowman J, Hammond R, et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 2006, 52(4): 587-593 (Pubitemid 44781171)
63. Plowey E D, Cherra S J, Liu Y J, et al. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem, 2008, 105(3): 1048-1056 (Pubitemid 351565713)
64. Sakaguchi-Nakashima A, Meir J Y, Jin Y, et al. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr Biol, 2007, 17(7): 592-598 (Pubitemid 46497793)
65. Deng J, Lewis P A, Greggio E, et al. Structure of the Roc domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci USA, 2008, 105(5): 1499-1504 (Pubitemid 351346543)
66. Hernandez D G, Paisan-Ruiz C, Mcinerney-Leo A, et al. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol, 2005, 57(3): 453-456 (Pubitemid 40343971)
67. Aasly J O, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol, 2005, 57(5): 762-765 (Pubitemid 40628869)
68. Ross O A, Toft M, Whittle A J, et al. Lrrk2 and Lewy body disease. Ann Neurol, 2006, 59(2): 388-393 (Pubitemid 43202496)